MX2024007861A - Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion. - Google Patents

Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion.

Info

Publication number
MX2024007861A
MX2024007861A MX2024007861A MX2024007861A MX2024007861A MX 2024007861 A MX2024007861 A MX 2024007861A MX 2024007861 A MX2024007861 A MX 2024007861A MX 2024007861 A MX2024007861 A MX 2024007861A MX 2024007861 A MX2024007861 A MX 2024007861A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
receptor agonist
preparation
application
stable pharmaceutical
Prior art date
Application number
MX2024007861A
Other languages
English (en)
Spanish (es)
Inventor
Yang Song
Jun Yu
Yan Han
Li Dong
Haohua Hao
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2024007861A publication Critical patent/MX2024007861A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2024007861A 2022-01-10 2023-01-09 Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion. MX2024007861A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210021736 2022-01-10
PCT/CN2023/071277 WO2023131325A1 (zh) 2022-01-10 2023-01-09 一种稳定的受体激动剂的药物组合物、制备方法及其应用

Publications (1)

Publication Number Publication Date
MX2024007861A true MX2024007861A (es) 2024-07-09

Family

ID=87073306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007861A MX2024007861A (es) 2022-01-10 2023-01-09 Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion.

Country Status (10)

Country Link
US (1) US20250170218A1 (https=)
EP (1) EP4464331A4 (https=)
JP (1) JP2024545887A (https=)
KR (1) KR20240135785A (https=)
CN (1) CN118488848A (https=)
AU (1) AU2023205290A1 (https=)
CA (1) CA3242599A1 (https=)
MX (1) MX2024007861A (https=)
TW (1) TW202333775A (https=)
WO (1) WO2023131325A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12102664B2 (en) * 2023-12-27 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating endocrine diseases and disorders
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
WO2025191149A1 (en) * 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
WO2026007980A1 (zh) * 2024-07-03 2026-01-08 上海海雁医药科技有限公司 一种mor受体激动剂的液体组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366692A (zh) * 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
AU2013205144B2 (en) * 2008-06-17 2015-07-16 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN113383014B (zh) * 2019-11-15 2024-06-18 江苏豪森药业集团有限公司 双受体重激动剂化合物及其药物组合物
EP4110800A1 (en) * 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用

Also Published As

Publication number Publication date
CN118488848A (zh) 2024-08-13
EP4464331A4 (en) 2025-05-07
CA3242599A1 (en) 2023-07-13
US20250170218A1 (en) 2025-05-29
TW202333775A (zh) 2023-09-01
JP2024545887A (ja) 2024-12-13
AU2023205290A1 (en) 2024-07-11
WO2023131325A1 (zh) 2023-07-13
KR20240135785A (ko) 2024-09-12
EP4464331A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
MX2024007861A (es) Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion.
PH12022551454A1 (en) Pyrazolyl derivatives useful as anti-cancer agents
ZA202210629B (en) Pharmaceutical composition comprising benzimidazole derivative compound
PH12023552774A1 (en) Nek7 inhibitors
WO2021252659A8 (en) Manufacture, formulation and dosing of apraglutide
PY0206703A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
MX2025006915A (es) Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta
MX2023012225A (es) Composiciones anestesicas de liberacion sostenida y metodos de preparacion de las mismas.
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
EP4295916A3 (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
MX2025013782A (es) Compuesto de sulfonamida, metodo de preparacion del mismo, y uso farmaceutico del mismo
PH12022550319A1 (en) Salt and crystal form of compound having agonistic activity to s1p5 receptor
PH12022552789A1 (en) Laminarin based formulation for agricultural applications
MX2025012133A (es) Derivados de tiadiazolona, composiciones y usos de estos
TN2023000279A1 (en) Oral solution based on citicoline and nicotinamide for use in the treatment of glaucoma
WO2010080339A4 (en) Phenylephrine formulations with improved stability
ZA202400915B (en) Pharmaceutical composition and use thereof
EP4592277A3 (en) Co-crystalline efinaconazole, and method for producing same
WO2022040111A3 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
ZA202200335B (en) Pharmaceutical composition of temozolomide.
MX2024011915A (es) Composicion en espray nasal bioadhesivo, proceso de preparacion y uso
PH12020551547A1 (en) Pharmaceutical preparation
WO2022184770A3 (de) Oraler dünnfilm
JOP20250188A1 (ar) مستحضر صيدلاني وطريقة تحضيره وتركيبة الأقراص